Hyaluronic acid-coated cationic nanostructured lipid carriers for oral vincristine sulfate delivery

References

• Kaushik T, Rahul PG, Abhay TS. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release 2013;170:15–40.
   PubMed Web of Science ®Google Scholar
• Lin YH, Liang HF, Chung CK. Physically crosslinked alginate/N,O-carboxymethyl chitosan hydrogels with calcium for oral delivery of protein drugs. Biomaterials 2005;26:2105–13.
   PubMed Web of Science ®Google Scholar
• Bromberg L. Polymeric micelles in oral chemotherapy. J Control Release 2008;128:99–112.
   PubMed Web of Science ®Google Scholar
• Laura ME, Richard C, Justin H. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 2012;64:557–70.
   PubMed Web of Science ®Google Scholar
• Elaint ML, Gary GL. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011;63:427–40.
   PubMed Web of Science ®Google Scholar
• Kassem LA, Gamal El-Din MM, Yassin NA. Mechanisms of vincristine-induced neurotoxicity: possible reversal by erythropoietin. Drug Discov Ther 2011;5:136–43.
   PubMedGoogle Scholar
• Noble CO, Guo Z, Hayes ME, et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 2009;64:741–51.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Silverman JA, Papadopoulos NE, et al. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol 2011;51:1205–12.
   PubMed Web of Science ®Google Scholar
• Dong HL, Na Z. Cancer chemotherapy with lipid-based nanocarriers. Crit Rev Ther Drug Carrier Syst 2010;27:371–417.
   PubMed Web of Science ®Google Scholar
• Rainer HM, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77.
   PubMed Web of Science ®Google Scholar
• Jing JL, Dian RZ, Lei LH, et al. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids Surf B Biointerfaces 2014;114:255–60.
   PubMed Web of Science ®Google Scholar
• Shamma RN, Aburahma MH. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomedicine 2014;9:5449–60.
   PubMed Web of Science ®Google Scholar
• Yaowaporn S, Kamonthip W, Kittisak L, et al. Modification of oral absorption of oxyresveratrol using lipid based nanoparticles. Colloids Surf B Biointerfaces 2015;131:182–90.
   PubMed Web of Science ®Google Scholar
• Radheshyam T, Kamla P. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 2011;415:232–43.
   PubMed Web of Science ®Google Scholar
• Eliana BS, Rainer HM. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Drug Deliv Handb Exp Pharmacol 2010;197:115–41.
   Google Scholar
• António JA, Eliana S. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007;59:478–90.
   PubMed Web of Science ®Google Scholar
• Yung CK, Cheng CW. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia. Colloids Surf B Biointerfaces 2013;101:101–5.
   PubMed Web of Science ®Google Scholar
• Liang L, Yu HT, Chao G, et al. Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf B Biointerfaces 2014;115:125–31.
   PubMed Web of Science ®Google Scholar
• Pedro F, Tiago N, Christiane G, et al. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv Transl Res 2011;1:299–308.
   PubMed Web of Science ®Google Scholar
• Dan L, Gai PL, Pei CL, et al. The enhancement of transfection efficiency of cationic liposomes by didodecyldimethylammonium bromide coated gold nanoparticles. Biomaterials 2010;31:1850–7.
   PubMed Web of Science ®Google Scholar
• Doktorovova S, Shegokar R, Rakovsky E, et al. Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies. Int J Pharm 2011;420:341–9.
   PubMed Web of Science ®Google Scholar
• Negi LM, Talegaonkar S, Jaggi M. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. Colloids Surf B Biointerfaces 2014;123:600–9.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials 2011;32:7181–90.
   PubMed Web of Science ®Google Scholar
• Han HS, Lee J, Kim HR, et al. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo. J Control Release 2013;168:105–14.
   PubMed Web of Science ®Google Scholar
• Huang PS, Yang CH, Liu JJ, et al. Improving the oral delivery efficiency of anticancer drugs by chitosan coated polycaprolactonegrafted hyaluronic acid nanoparticles. J Mater Chem B 2014;2:4021–33.
   PubMed Web of Science ®Google Scholar
• Yang XY, Li YX, Li M, et al. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 2013;334:338–45.
   PubMed Web of Science ®Google Scholar
• Han L, Zhao YF, Yin LF, et al. Insulin-loaded pH-sensitive hyaluronic acid nanoparticles enhance transcellular delivery. AAPS PharmSciTech 2012;13:836–45.
   PubMed Web of Science ®Google Scholar
• Choi KY, Yoon HY, et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011;5:8591–9.
   PubMed Web of Science ®Google Scholar
• Koichi I, Adchara P, Yuichi T, et al. Nanoparticle formation of poorly water-soluble drugs from ternary ground mixtures with PVP and SDS. Chem Pharm Bull 2003;51:171–4.
   PubMed Web of Science ®Google Scholar
• Gui XL, Peng Z, Wen PZ, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 2010;148:241–8.
   PubMed Web of Science ®Google Scholar
• Gal JG, Dana K, Yosi S, et al. Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Pharm Res 2012;29:1121–33.
   PubMed Web of Science ®Google Scholar
• Fenger R, Fertitta E, Kirmse H, et al. Size dependent catalysis with CTAB-stabilized gold nanoparticles. Phys Chem Chem Phys 2012;14:9343–9.
   PubMed Web of Science ®Google Scholar
• Korsmeyer SJ, Shutter JR, Veis DJ, et al. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993;4:327–32.
   PubMed Web of Science ®Google Scholar
• Zhang TC, Chen JN, Zhang Y, et al. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011;43:174–9.
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996;13:1838–45.
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Benoit JP, et al. The gastrointestinal stability of lipid nanocapsules. Int J Pharm 2009;379:260–5.
   PubMed Web of Science ®Google Scholar
• Lim SJ, Lee MK, Kim CK. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release 2004;100:53–61.
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995;125:91–7.
   Web of Science ®Google Scholar